Erythromycin
What studies of erythromycin found
At a glance, by condition
ME/CFS: D Little or no difference
Based on the strongest evidence, studies with no comparison group (very low certainty): 3 of 4 findings are D.
4 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Studies found little or no difference with erythromycin for ME/CFS. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- CMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- Erythromycin · ME/CFS is hereDLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
ME/CFS
Symptoms
Sleep1 study · 22 people took erythromycin Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (22 in all).
Studies with no comparison group70 in the study · 22 with outcome data · 6 days · 400 mg b.d, at Day 8 for 6 days
Sleep improved.
The evidence is very uncertain about the effect of erythromycin on sleep in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (22 in all)
See the 1 study
-
- People in the study
- 70 in the study · 22 with outcome data
- Dose
- 400 mg b.d, at Day 8 for 6 days
- Outcome
- subjective sleep quality sleep diary
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Fatigue1 study · 22 people took erythromycin Little or no difference D
Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (22 in all).
Studies with no comparison group70 in the study · 22 with outcome data · 6 days · 400 mg b.d, at Day 8 for 6 days
No clear change in fatigue.
The evidence is very uncertain about the effect of erythromycin on fatigue in ME/CFS. Little or no difference · very low certainty D
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (22 in all)
Combination: Erythromycin + Probiotics and fermented foods44 in the study
Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome: neuropsychological symptoms and sex comparisons. (2018): fatigue, no clear difference.
Shown, not counted: erythromycin was given together with other treatments.
See the 1 study
-
- People in the study
- 70 in the study · 22 with outcome data
- Dose
- 400 mg b.d, at Day 8 for 6 days
- Outcome
- Chalder Fatigue Scale
- Effect
- no clear difference
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Low mood or anxiety1 study · 22 people took erythromycin Little or no difference D
Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (22 in all).
Studies with no comparison group70 in the study · 22 with outcome data · 6 days · 400 mg b.d, at Day 8 for 6 days
No clear change in low mood or anxiety.
The evidence is very uncertain about the effect of erythromycin on low mood or anxiety in ME/CFS. Little or no difference · very low certainty D
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (22 in all)
See the 1 study
-
- People in the study
- 70 in the study · 22 with outcome data
- Dose
- 400 mg b.d, at Day 8 for 6 days
- Outcome
- POMS subscales Profile of Mood States Short Form
- Effect
- no clear difference
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Daily life and health overall
Overall symptoms1 study · 22 people took erythromycin Little or no difference D
Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (22 in all).
Studies with no comparison group70 in the study · 22 with outcome data · 6 days · 400 mg b.d, at Day 8 for 6 days
No clear change in overall symptoms.
The evidence is very uncertain about the effect of erythromycin on overall symptoms in ME/CFS. Little or no difference · very low certainty D
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (22 in all)
Combination: Erythromycin + Probiotics and fermented foods44 in the study
Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome: neuropsychological symptoms and sex comparisons. (2018): self-reported total symptoms (SSH), better.
Shown, not counted: erythromycin was given together with other treatments.
See the 1 study
-
- People in the study
- 70 in the study · 22 with outcome data
- Dose
- 400 mg b.d, at Day 8 for 6 days
- Outcome
- CFS symptoms total ratings score Symptoms Severity Profile
- Effect
- no clear difference
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Studies of combinations
Outcomes that only studies of erythromycin given together with other treatments looked at. Shown, not graded: they can’t tell what erythromycin did alone.
Cognition (brain fog) ME/CFS
Combination: Erythromycin + Probiotics and fermented foods44 in the study
Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome: neuropsychological symptoms and sex comparisons. (2018): cognitive flexibility, better.
Shown, not counted: erythromycin was given together with other treatments.
Side effects
Stopping because of side effects1 study
one withdrew from the study as the patient became unwell
Sleep quality and the treatment of intestinal microbiota imbalance in Chronic Fatigue Syndrome: A pilot study. (2015)
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
400 mg at the start
- 2Top dose
Most often 400 mg (2 of 2 studies)
Doses across 2 studies
400 to 400 mg.
Each study’s dose, as printed
- 400 mg b.d, at Day 8 for 6 days Sleep quality and the treatment of intestinal microbiota imbalance in Chronic Fatigue Syndrome: A pilot study. (2015)
- 400 mg, twice daily during weeks 2 and 4 Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome: neuropsychological symptoms and sex comparisons. (2018)
All papers
- The value of the dehydroepiandrosterone-annexed vitamin C infusion treatment in the clinical control of chronic fatigue syndrome (CFS). I. A Pilot study of the new vitamin C infusion treatment with a volunteer CFS patient.1996 · compared with another group
Summary
This pilot study followed a single male volunteer with chronic fatigue syndrome (CFS) from August 1995 to May 1996. The paper does not report where the patient was from or how he was selected. An annex-free vitamin C drip infusion set (the old set) and a dehydroepiandrosterone-annexed vitamin C infusion set (the new set) were prepared. The patient also received oral erythromycin and chloramphenico; the abstract does not give doses, schedules or durations for the infusion sets or antibiotics. The report describes the first, second and 3rd stages of disease. From August to October 1995, the old infusion together with short-term antibiotics was found effective for control of pneumonia. From November 1995 to January 1996, signs of pneumonia recurrence became eminent despite moderate frequency of the old treatment and stepwise prolongation of antibiotics. From February to May 1996, alternating the old and new infusions together with long-term antibiotics led to substantial extinction of pneumonia signs (leucocytosis, tachycardia etc). An immunological survey of lymphocyte subsets including NK cell percent failed to find a coherent change. Side effects and withdrawals were not reported. No enrolled or analysed counts, and no comparison-group numbers, are reported. The authors state no limitations in the abstract.
- Sleep quality and the treatment of intestinal microbiota imbalance in Chronic Fatigue Syndrome: A pilot study.2015 · no comparison group · 70 in the study · 22 with outcome data
- Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome: neuropsychological symptoms and sex comparisons.2018 · combination: given with other treatments · 44 in the study
Summary
This open-label, non-randomised pilot with repeated measures and no comparison group examined an antibiotic/probiotic intervention in 44 adult ME/CFS patients (27 females) from one specialist medical clinic with Streptococcus viable counts above 3.00 × 105 cfu/g. Treatment was Erythromycin 400 mg twice daily during weeks 2 and 4, alternating with Pro4-50 d-lactate free multistrain probiotic two capsules daily during weeks 3 and 5, within a 4-week treatment protocol across 6 weeks. Outcomes included sleep, mood, cognition, fatigue, total symptoms, microbiota and urine d:l lactate ratio. Actigraphic sleep efficiency did not change (M = 83.94 to M = 83.80; partial eta squared = .03, p < .297). RVP A′ improved from M = .91 to M = .94 (partial eta squared = .53, p < .001), and SSH total symptoms reduced from M = 28.42 to M = 22.76 (partial eta squared = .29, p = .001). Mood, fatigue and urine d:l lactate ratio remained similar across time. Sex-time interactions revealed no large effects and did not support a sex-specific response. Six unexpected adverse events were reported from five participants; one discontinued all treatment after the first antibiotic dose. The authors state the open-label design and practice effects limit interpretation.